苯妥英治疗强迫症的双盲对照研究

The study of phenytoin in the treatment of obsessive-compulsive disorder with doubleblind, placebo-controlled trial

符合DSMⅢ—R和CCMD—2诊断标准的62例强迫症患者,随机分为三组:氯丙咪嗪组(22例)、苯妥英组(20例)、安慰剂组(20例),采用双盲对照研究法,每组经4周治疗,在治疗前后,经Y-BOCS、MSCPOR、HAMD量表测定及临床疗效评定。资料提示氯丙咪嗪组、苯妥英组、安慰剂组的痊愈,显进者分别为68％、55％、0％,而Y-BOCS、MSCPOR减分率分别为54.6％、46.05％、3.2％。提示氯两咪嗪组、苯妥英组对治疗强迫症明显优于安慰剂组。

Sixty-two patients who met the DSM Ⅲ -R and CCMD-2 criteria for obsessive-compulsive disorder, randomly divided into three groups ; chlorimipramine group ( N = 22 ) , phenytoin group (N = 20), and placebo group (N = 20), with double-blind, placebo-controlled study. Each group was treated for 4 weeks. Before and after 4-week treatment, the Y-BOCS, MSCPOR, HAMD rating scales were measured, and the clinical effects were also evaluated. The data revealed that the percentage of full recovery and improvement in the chlormipramine, phenytoin, placebo groups were 68%, 55%, 0%, respectively. The mean reduction in the Y-BOCS, MSCPOR , rating seal of chlorimipramine, phenytoin, placebo groups at the end of 4 -week of treatment were 54. 69% , 46- 05% , 6. 94%and 18.88%, 22.13%, 3-2%, respectively. The results suggest that both chlorimipramine and phenytoin were effective in the treatment of obsessive-compulsive disorder.